GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Capex-to-Operating-Income

Curatis Holding AG (XSWX:CURN) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Curatis Holding AG's Capital Expenditure for the six months ended in Jun. 2024 was CHF0.00 Mil. Its Operating Income for the six months ended in Jun. 2024 was CHF-3.30 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Curatis Holding AG Capex-to-Operating-Income Historical Data

The historical data trend for Curatis Holding AG's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Capex-to-Operating-Income Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - -

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial - - - - -

Competitive Comparison of Curatis Holding AG's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curatis Holding AG's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Curatis Holding AG's Capex-to-Operating-Income falls into.


;
;

Curatis Holding AG Capex-to-Operating-Income Calculation

Curatis Holding AG's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.535
=N/A

Curatis Holding AG's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.297
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curatis Holding AG  (XSWX:CURN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Curatis Holding AG Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Curatis Holding AG Business Description

Traded in Other Exchanges
Address
Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.